MY ACCOUNT | NEWSLETTER |

Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership


Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the launch of its new Sustainable Solutions Platform (SSP), a companywide initiative designed to help animal protein, dairy and petfood producers address greenhouse gas emissions through practical, science-based solutions that integrate seamlessly into existing feed and production systems.

As part of the SSP launch, Phibro is introducing Verratain™ Verified Sustainability Solutions, the Company’s first master brand for sustainable products that can significantly lower emissions across animal protein and petfood supply chains. The initial Verratain product line is being launched through a strategic partnership with VAXA Technologies and is based on VAXA Technologies’ low carbon, high value microalgae feed materials that enable efficient supply chain decarbonization.

The first two products under the Verratain brand are Verratain™ Spirulina and Verratain™ Omega Oil, which are low-carbon microalgae feed ingredients. When these products are incorporated into the animal's diet as a nutrition source, producers can materially reduce the carbon intensity of animal feed to allow organizations to meet their sustainability goals while supporting animal health. “Our Verratain Verified Sustainability Solutions represent a natural evolution of Phibro’s portfolio as our customers increasingly seek credible, scalable sustainability solutions,” said Dani Bendheim, incoming Chief Executive Officer of Phibro Animal Health Corporation. “These offerings complement our existing animal health and nutrition solutions while directly addressing the evolving sustainability needs of animal protein and petfood producers and their downstream customers.”

Targeting a Major Scope 3 Emissions Hotspot

The World Benchmarking Alliance reports that 165 of the world’s 350 most influential food and agriculture companies have disclosed Scope 3 climate commitments, which typically call for 20–30% reductions in value‑chain emissions by 2030. At scale, this implies an estimated $80–300 billion per‑year decarbonization value signal under SBTi‑aligned internal carbon pricing. (Source: World Business Council for Sustainable Development. 2024. Scope 3 Navigator for Agri-Food. Available: https://cecodes.org.co/wp-content/uploads/2026/02/WBCSD-AF-C-suite-Scope-3-Navigator-deck.pdf Accessed: May 1, 2026).

Feed is typically the largest source of Scope 3 emissions for livestock, poultry and aquaculture producers. By focusing on feeding a low carbon alternative nutrient source, Verratain directly targets one of the most significant emissions drivers in animal protein supply chains.

Verratain Spirulina and Verratain Omega Oil are produced by VAXA Technologies in their proprietary state of the art indoor cultivation platform directly connected to renewable geothermal energy, clean water resources, and controlled growing conditions. The production process yields low‑carbon feed material that is designed to seamlessly integrate with existing feeding systems. The program utilizes life cycle assessment-based solutions to create effective Scope 3 decarbonization which is incorporated into the product’s life-cycle assessments, in accordance with leading international standards such as the Greenhouse Gas Protocol.

Leadership to Build and Scale the Platform

To lead the Sustainable Solutions Platform and the Verratain portfolio, Phibro recently appointed Peter Bunce as Head of Sustainable Solutions. Bunce brings more than two decades of experience in agricultural sustainability and voluntary carbon markets, including building large‑scale programs that connect farmers with downstream consumer packaged goods companies and retailers.

“I joined Phibro because of its deep integration across global protein and dairy supply chains, where scalable solutions can deliver meaningful emissions reductions,” said Bunce. “After many years working in agricultural voluntary emissions markets, I have rarely seen innovations that combine impact and practicality like Verratain.”

Advancing a More Efficient and Resilient Food System

The launch of the Verratain product line marks a pivotal commercial milestone for Phibro’s sustainability initiatives. The Company anticipates the commencement of initial sales within the coming months, providing early adopters with a first-to-market opportunity to integrate these low-carbon microalgae solutions into their production systems.

Looking ahead, Phibro views the Sustainable Solutions Platform as a long‑term growth business that will expand beyond the initial products and partnership. 

About VAXA Technologies

VAXA is a food tech / climate tech company that has successfully industrialized its patented, carbon-negative microalgae production platform, to deliver proven, scalable solutions. By leveraging renewable energy, waste streams, and machine learning, VAXA produces high-value ingredients that physically remove emissions from the global supply chain, allowing partners to decarbonize at the source. Unlike traditional, resource-heavy algae production, VAXA’s modular, indoor facility in Iceland achieves a 100x higher decarbonization impact using less than 1% of the resources required by conventional methods, utilizing a bio secured optimized environment to ensure a consistent, food-grade output that provides a reliable, superior supply chain for corporations looking to improve their products and meet their sustainability goals.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. The Company strives to be a trusted partner to livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions that help maintain and enhance animal health.


Source: www.pahc.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Undergrad researchers drive discovery in the College of Veterinary Medicine

Like0
Dislike0

Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study

Like0
Dislike0

Gut Microbiome and Osteoarthritis: Insights From the Naturally Occurring Canine Model of Osteoarthritis

Like0
Dislike0

Insights in the Development and Uses of Alternatives to Antibiotic Growth Promoters in Poultry and Swine Production

Like0
Dislike0

The Cat that Always Lands on His Feet at Foster Hospital

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top